Can OX40 Agonists Increase the Potency of COVID-19 Vaccines?
Publication Title
8th Annual Immuno-Oncology Virtual Summit, Oct 6-8, 2020
Document Type
Abstract
Publication Date
10-8-2020
Keywords
2019-nCoV
Abstract
Eliciting a potent long-lasting immune response (e.g. Ab, CD4, and CD8 T cells) against the SARS-CoV-2 virus with a vaccine will most likely be essential to reduce morbidity and mortality during future waves of viral propagation. To this end our lab has been working on a way to increase the potency of vaccines for 20 years through engagement of the TNF-receptor family member, OX40. This talk will cover the data generated over the last 20 years in vaccinated hosts boosted with OX40 agonists and present preliminary data in mice injected with a COVID-19 vaccine w/wo OX40 agonists.
Clinical Institute
Cancer
Specialty
Earle A. Chiles Research Institute
Specialty
Oncology
Specialty
Infectious Diseases
